Revenue Breakdown
Composition ()
No data
Revenue Streams
Biomerica Inc (BMRA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical Lab, accounting for 56.0% of total sales, equivalent to $627.00K. Other significant revenue streams include Contract Manufacturing and OTC. Understanding this composition is critical for investors evaluating how BMRA navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Biomerica Inc maintains a gross margin of 4.21%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -113.47%, while the net margin is -109.09%. These profitability ratios, combined with a Return on Equity (ROE) of -84.30%, provide a clear picture of how effectively BMRA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BMRA competes directly with industry leaders such as CELZ and AGPU. With a market capitalization of $6.28M, it holds a significant position in the sector. When comparing efficiency, BMRA's gross margin of 4.21% stands against CELZ's -3019.27% and AGPU's -130.96%. Such benchmarking helps identify whether Biomerica Inc is trading at a premium or discount relative to its financial performance.
